Results 101 to 110 of about 8,310 (238)

RWE in Europe Paper II: The use of Real World Evidence in the disease context

, 2017
Real World Evidence (RWE), the use of data not collected via traditional randomised controlled trials (RCT) for decision-making, is becoming more interesting to market-access and reimbursement decision-makers, despite potential methodological issues ...
Gill, Jennifer, Kossler, Ingrid, Thomas, Michael, Spandonaro, Federico, Duncombe, Robert, Wartenberg, Markus, Schramm, Wolfgang, Albanell, Joan, Kanavos, Panos, Fink-Wagner, Antje, Podrazilova, Katerina, Dank, Magdolna, Jahnz-Różyk, Karina, Hutton, John   +13 more
core   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6280-6290, July 2026.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6291-6300, July 2026.
ABSTRACT Aim To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan.
Takeshi Miyatsuka, James Brash, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam   +6 more
wiley   +1 more source

Resolution based on the results of the V annual scientific-practical conference "RWD/RWE. Possible and real"

Реальная клиническая практика: данные и доказательства
On September 19, 2024, in Moscow (Russian Federation), the V annual scientific-practical conference with international participation "RWD/RWE. Possible and Real" were organized and held.
A. S. Kolbin, M. A. Borzova, D. Yu. Belousov, V. V. Kalinichenko   +3 more
doaj   +1 more source

Management analysis of the company RWE Transgas a.s.

, 2011
Bakalářská práce se zabývá rozborem výsledků hospodaření společnosti RWE Transgas, a.s. Teoretická část je věnována charakteristice finanční analýzy. Jsou zde vymezeny základní pojmy, metody, ukazatele a hodnotící modely celkové finanční situace podniku.
Fritz, Martin
core  

Der Eon/RWE-Deal : Marktbeherrschung und Shareholder Value-Politik mit behördlicher Zustimmung [PDF]

, 2020
Am 17. September 2019 hat die EU-Wettbewerbs-Kommissarin Margrethe Vestager dem Stromkonzern Eon die Übernahme und Zerschlagung der RWE-Tochter Innogy unter leichten Auflagen erlaubt.
Berlo, Kurt, Wagner, Oliver
core  

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, Volume 117, Issue 1, Page 174-185, July 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)

ESMO Real World Data and Digital Oncology
Background: The role of real-world evidence (RWE) for clinical efficacy regulatory evaluation remains unclear. We aimed to assess and describe the reported use of RWE for clinical efficacy evaluation of authorised targeted therapies for treatment of ...
J.W.G. Derksen, D. Martins-Branco, A. Valachis, A. Pellat, S.C.M.W. van Nassau, A. Aggarwal, G. Pentheroudakis, M. Koopman, L. Castelo-Branco, S. Delaloge   +9 more
doaj   +1 more source

Wertorientierte Unternehmensführung bei RWE

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung, 2000
The main concept of performance measurement in the RWE-Group is a rate of return on invested capital. A positive spread between the rate of return on invested capital and the cost of capital rate is the main value driver. The required target-return on invested capital for business units is determined by a benchmark analysis.
openaire   +1 more source